The company maintains a zero-revenue profile while operating losses expanded to $22.1 million in 2026Q1, driven by a surge in R&D spending to $14.6 million.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 82K | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | -82K | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - |
| Operating Expenses | 46.78M | 30.4M | 64.83M | 11.38M | 2.81M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 18.21M | 13.66M | 13.66M | 3.53M | 1.46M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 28.47M | 16.74M | 51.17M | 7.84M | 1.35M |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 100K | 0 | 0 | 0 | 0 |
| Operating Income | -46.86M | -30.4M | -64.83M | -11.38M | -2.81M |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | 53.1% | -469.88% | -304.98% | - |
| EBITDA | -46.54M | -30.08M | -64.74M | -11.37M | -2.81M |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | - | 53.53% | -469.28% | -305.13% | - |
| D&A (Non-Cash Add-back) | 325.5K | 321K | 91K | 4K | 2K |
| EBIT | -46.51M | -30.4M | -63.1M | -1.45M | -12.2M |
| Net Interest Income | 6.56M | 3.92M | 1.72M | -4.01M | -2.08M |
| Interest Income | 6.36M | 3.92M | 1.72M | 811K | 73K |
| Interest Expense | -206.5K | 0 | 0 | 4.83M | 2.15M |
| Other Income/Expense | 7.69M | 5.2M | 1.73M | 5.1M | -11.54M |
| Pretax Income | -39.17M | -25.2M | -63.1M | -6.27M | -14.35M |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 1K | 1K | 1K | 1K | 1K |
| Effective Tax Rate % | -0% | -0% | -0% | -0.02% | -0.01% |
| Net Income | -39.17M | -25.2M | -63.1M | -6.28M | -14.35M |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | - | 60.06% | -905.61% | 56.27% | - |
| Net Income (Continuing) | -39.17M | -25.2M | -63.1M | -6.28M | -14.35M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.39 | -1.00 | -17.83 | -1.77 | -4.05 |
| EPS Growth % | - | 94.39% | -907.34% | 56.3% | - |
| EPS (Basic) | - | -1.00 | -17.83 | -1.77 | -4.05 |
| Diluted Shares Outstanding | 28.24M | 25.3M | 3.54M | 3.54M | 3.54M |
| Basic Shares Outstanding | 28.24M | 25.3M | 3.54M | 3.54M | 3.54M |
| Dividend Payout Ratio | - | - | - | - | - |
Clinical trial failure risk
As reported in recent financial statements, LBRX's R&D expenditure surged to $14.6 million in 2026Q1, reflecting a significant acceleration in clinical trial activity that underscores the company's transition into more resource-intensive development phases while maintaining a zero-revenue profile throughout the observed ten-quarter historical period.
The sharp increase in R&D spending suggests that the company is aggressively funding late-stage clinical milestones for its lead candidate, LB-102. Investors should monitor whether this elevated burn rate remains sustainable given the lack of commercial revenue and the inherent volatility of CNS drug development timelines.
Based on the provided income statement data, LBRX continues to exhibit a negative operating margin profile, with operating losses widening to $22.1 million in 2026Q1 as the company scales its overhead and research infrastructure without any corresponding top-line growth to offset these rising operational costs.
The absence of revenue means that operating leverage cannot be realized, leaving the company entirely dependent on its $250 million cash position to fund ongoing operations. This structure implies that any further expansion in SG&A or R&D will directly exacerbate the net loss, placing significant pressure on capital allocation efficiency.
According to the company's reported figures, net losses have expanded significantly to $19.1 million in 2026Q1, a trend that highlights the high-risk nature of the firm's current financial position as it prioritizes clinical development over the attainment of any near-term profitability or positive cash flow generation.
The volatility in EPS, which reached -0.67 in 2026Q1, reflects the heavy reliance on external funding to sustain operations. Analysts should be cautious of the potential for future dilutive financing events, as the current earnings quality is fundamentally constrained by the lack of a commercialized product to support the cost base.
While the company maintains a $250 million cash reserve, the recent jump in quarterly operating losses to $22.1 million warrants investigation into whether the current capital runway is sufficient to reach critical clinical readouts without requiring additional, potentially dilutive, equity financing in the near future.
Short-term observers may focus on the rapid depletion of cash relative to the clinical progress of LB-102. If the company fails to demonstrate clear efficacy in its upcoming trials, the current cost structure may prove unsustainable, forcing a strategic pivot or a significant reduction in research scope.
Quick answers to the most common questions about buying LBRX stock.
For fiscal year 2025, LB Pharmaceuticals Inc Common Stock (LBRX) reported total revenue of $0.0M.
LB Pharmaceuticals Inc Common Stock (LBRX) reported a net loss of $25.2M for the fiscal year ending 2025.